A genetically engineered bacterium for producing steroid drug precursor and its application

By enhancing the expression of AccA1, AccD1, AraC and Nat genes in microorganisms, the low conversion rate problem caused by the accumulation of propionyl Coenzyme A in strains in microorganisms was solved, and the production efficiency and cost-effectiveness of steroid precursors were improved.

CN115838679BActive Publication Date: 2024-11-01TIANJIN UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211237829.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-10
Publication Date
2024-11-01
Estimated Expiration
2042-10-10

AI Technical Summary

Technical Problem

During the production process of microbial forensic precursors, the accumulation of propionyl Coenzyme A in the strain results in a low conversion rate of sterol per unit time, which increases production costs.

Method used

By strengthening the expression of AccA1, AccD1, AraC, and Nat genes in the host bacteria, genetically engineered bacteria are constructed to improve the metabolic capacity of propionyl Coenzyme A, thereby improving sterol conversion and production efficiency.

Benefits of technology

It significantly improves the conversion rate and production efficiency of steroidal precursors, reduces industrial production costs, and enhances the tolerance and vitality of the strain.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115838679B_ABST
    Figure CN115838679B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biocatalysis technology, and specifically relates to a method for combining the reduction of propionyl-CoA in cells of steroidal drug precursor producing bacteria to produce high-yield steroidal drug precursors. The present invention achieves high yield of steroidal drug precursors by enhancing the AccA1 and AccD1 genes of the Acc family, the transcriptional regulatory factor AraC gene and the Nat gene regulated by the gene in the steroidal drug precursor producing strain alone or in combination. During the substrate conversion period, the content of the substrate metabolic byproduct propionyl-CoA in the cells of the obtained genetically engineered bacteria is significantly lower than that of the original bacteria, the conversion efficiency of AD is significantly improved, and the strain's tolerance to the environment, especially the tolerance to the product, provides new ideas for industrial production.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biocatalysis, and more specifically relates to a strain for jointly reducing propionyl-CoA and high-producing steroid drug precursors and application thereof. Background Art

[0002] Steroid compounds are essential for the normal functioning of organisms. When the body's own production is insufficient, it needs to actively ingest such steroid compounds to supplement the body's normal needs. Currently, there are hundreds of steroid drugs on the market, which are widely used in clinical practice as diuretics, anti-inflammatory drugs, steroid hormone immune antigens and cardiovascular drugs, which leads to a strong demand for the precursors of such drugs.

[0003] The industrial production of steroidal drug precursors mainly utilizes microbial transformation methods to separate and purify cheap and easily available raw materials such as phytosterols, β-sitosterol, ergosterol, cholesterol, etc. through microbial metabolism to obtain multifunctional and high-value steroidal drug precursors. Using phytosterols as raw materials, the steroidal drug precursors that can be produced mainly include C19-steroids (AD, ADD, 9-OHAD) and C22-steroids (20-carboxyl-pregnane-4-ene-3-one, 4-BNC, 20-hydroxymethyl-pregnane-4-ene-3-one, 4-BNA). Among them, androstenedione (AD) can be used to produce androgens, anabolic hormones, spironolactone and other drugs; androstenedione (ADD) generated by dehydrogenation of AD at C1,2 can be used to synthesize 19-norsteroidal estrogens, such as estrone, norethisterone and progestin. In addition to synthesizing sex hormones, the corticosteroid side chain can be introduced into the keto group of AD so that it can be used in the production of corticosteroids, or more types of steroid intermediates can be produced by hydroxylation at different sites, such as 9α-OH-AD, 5α-OH-AD, 11α-OH-AD, etc. It can be seen that AD can synthesize almost all steroid drugs, so it is extremely popular in the market. At present, the market size of steroid precursors ranks second in the drug market.

[0004] In the process of sterol metabolism to produce AD, microorganisms can generate one molecule of AD, one molecule of acetyl-CoA and three molecules of propionyl-CoA by initial oxidation and side chain degradation of one molecule of β-sitosterol. In order to increase the conversion rate of sterol to AD per unit time, genetic engineering and mutagenesis are usually used to strengthen the sterol metabolic pathway of microorganisms, which causes the byproduct propionyl-CoA to accumulate excessively in the cell. Its accumulation will seriously inhibit the activity of some key metabolic enzymes related to life, such as pyruvate dehydrogenase, and affect the activity of the strain, thereby limiting the yield of AD and increasing the cost of industrial production. Summary of the invention

[0005] The purpose of the present invention is to provide a method for reducing propionyl-CoA in the cells of steroid precursor production bacteria, and to construct genetically engineered bacteria using the method, thereby solving the problem that during the production of steroid precursors by microbial methods, the accumulation of propionyl-CoA by the strain leads to a low sterol conversion rate per unit time, which in turn leads to a high price of steroid precursors. In order to solve the above technical problems, the present invention adopts the following technical solutions:

[0006] One of the technical solutions provided by the present invention is a genetically engineered bacterium with high production of steroidal drug precursors, which is constructed by overexpressing or combining AccA1, AccD1, AraC, and Nat genes in a host bacterium, thereby enhancing the metabolic ability of the above genes to propionyl-CoA in the steroidal drug precursor production bacterium, thereby improving the sterol conversion rate and production efficiency;

[0007] The host bacteria of the genetically engineered bacteria are bacteria or fungi capable of producing steroidal drug precursors;

[0008] The bacteria or fungi capable of producing steroidal drug precursors may be mycobacterium microorganisms or Rhodococcus microorganisms;

[0009] Further, the mycobacterium microorganism is selected from Mycobacterium sp. NRRLB-3683, Mycobacterium sp. NRRLB-3805, Mycobacterium smegmatism, Mycobacterium fortuitum, Mycobacterium gilvum, Mycobacterium neoaurum, Mycobacterium Phlei, Mycobacterium avium, etc.;

[0010] Preferably, the Mycobacterium microorganism is Mycobacterium sp. MNR M3ΔKsdD (hereinafter referred to as MNR).

[0011] The steroidal drug precursors include but are not limited to hydroxylated derivatives such as androst-4-ene-3,17-dione (AD), androst-1,4-diene-3,17-dione (ADD), and 9α-hydroxyandrost-4-ene-3,17-dione (9α-hydroxyandrost-4-ene-3,17-dione, 9α-OH-AD), and A-ring degradation products;

[0012] Furthermore, the genes involved in the metabolism of propionyl-CoA include the AccA1 and AccD1 genes encoding propionyl-CoA carboxylase, the AraC gene, a transcriptional regulator responsible for regulating the expression of acyltransferase, and the Nat gene encoding propionyl-CoA transferase regulated by the AraC gene:

[0013] The AccA1, AccD1, AraC, and Nat genes are all derived from the fast-growing Mycobacterium sp. MNR M3, numbered CICC 21097;

[0014] The AccA1 gene has a nucleotide sequence shown in SEQ ID NO: 1;

[0015] The AccD1 gene has a nucleotide sequence shown in SEQ ID NO: 2;

[0016] The AraC gene has a nucleotide sequence shown in SEQ ID NO: 3;

[0017] The Nat gene has a nucleotide sequence shown in SEQ ID NO: 4;

[0018] Preferably, the AccA1 and AraC genes are expressed in tandem in the host mycobacterium MNR to obtain a genetically engineered bacterium with a high production of steroid drug precursors.

[0019] The second technical solution provided by the present invention is the use of the genetically engineered bacteria described in the first technical solution in the production of steroidal drug precursors;

[0020] Furthermore, the method for producing AD by fermentation using the strain is as follows:

[0021] The seed liquid of the genetically engineered strain is transferred to the fermentation medium at an inoculation rate of 1%-10%, and cultured at 25-37°C and 100-200rpm for 24-168h to obtain a sterol molar conversion rate of 60%-99%;

[0022] Furthermore, the fermentation medium is composed of: (NH4)2HPO4 0.1-4g / L, K2HPO4 0.1-3g / L, MgSO40.1-3g / L, ammonium ferric citrate 0.01-0.2g / L, citric acid 1-5g / L, reducing sugar 5-50g / L, sterol 1-50g / L, and the rest is water, pH 6.0-7.5, and is used after high-pressure steam sterilization.

[0023] Beneficial effects:

[0024] The present invention obtains strain MNR M3 by overexpressing AccA1 gene in steroid precursor producing strain MNR alone

[0025] △KsdD-AccA1 (hereinafter referred to as MNR-A), during the fermentation process, its highest AD conversion rate reached 92.58%, which was 9.62% higher than the AD conversion rate of the starting strain MNR under the same period; by overexpressing the AccD1 gene alone in MNR, the strain MNR M3△KsdD-AccD1 (hereinafter referred to as MNR-D) was obtained, during the fermentation process, its highest AD conversion rate reached 89.18%, which was 6.23% higher than the AD conversion rate of the starting strain MNR under the same period; by overexpressing the AraC gene alone in the steroid precursor producing bacteria MNR, the strain MNR M3△KsdD-AraC (hereinafter referred to as MNR-C) was obtained, during the fermentation process, its highest AD conversion rate reached 90.68%, which was 7.73% higher than the AD conversion rate of the starting strain MNR under the same period; by overexpressing the Nat gene alone in the steroid precursor producing bacteria MNR, the strain MNR During the fermentation process, the highest AD conversion rate of M3△KsdD-Nat (hereinafter referred to as MNR-N) reached 89.25%, which was 6.30% higher than that of the starting strain MNR under the same condition.

[0026] It was also found that in an antibiotic environment, even if MNR-C carries an exogenous plasmid, its growth efficiency can be consistent with that of the original strain, while MNR-A has good sterol conversion ability, but its growth efficiency is slow. Combining the advantages of both, the AccA1-AraC tandem gene overexpression strain MNR M3△KsdD-AccA1-AraC (hereinafter referred to as MNR-AC) was constructed. The MNR-AC strain can resist the growth load caused by the overexpression of the AccA1 gene on the strain in the early stage of fermentation, and the growth efficiency is maintained at a similar level with the starting strain MNR. During the fermentation process, the highest AD conversion rate of the tandem strain MNR-AC can reach 94.11%, and its AD production reaches the highest at 144h of fermentation, which is significantly different from the AD production of MNR, MNR-A and MNR-C at the same time. At the same time, it can reach the production of MNR-A and MNR-C at 168h. In summary, MNR-AC is higher than other strains, not only improving its conversion rate, but also shortening the fermentation cycle. This effect also shows that the AraC gene can be expressed in tandem with other overexpressed genes to reduce the load of exogenous plasmids on strain growth and improve strain vitality. This tandem expression system has a wide range of application value and provides a new method for reducing the production cost of steroid drug precursors.

[0027] At the same time, it was found beyond the present invention that when AccA1-AraC is overexpressed in series, the strain's tolerance to the environment, especially to the product, can be enhanced. After experiments, the growth of the strain MNR-AC was measured at different AD concentrations, and it was found that the biomass of MNR-AC increased in high concentrations of sterols, was less affected by AD concentration, and had improved tolerance to the product than the starting strain MNR. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Schematic diagram and electrophoresis diagram of single gene overexpression pMV-261-AccA1 plasmid;

[0029] Figure 2 Single gene overexpression pMV-261-AccD1 plasmid pattern and electrophoresis;

[0030] Figure 3 Schematic diagram and electrophoresis diagram of single gene overexpression pMV-261-AraC plasmid;

[0031] Figure 4 Schematic diagram and electrophoresis diagram of single gene overexpression pMV-261-NAT plasmid;

[0032] Figure 5 Changes in intracellular propionyl-CoA content in single gene overexpression strains during AD transformation;

[0033] Figure 6Growth curve of single gene overexpression strain;

[0034] Figure 7 AD molar conversion rate of single gene overexpression strain;

[0035] Figure 8 Electrophoresis of tandem gene overexpression plasmid;

[0036] Fig. 9 Growth curve of tandem gene overexpression strain;

[0037] Fig.10 AD molar conversion rate and yield of tandem gene overexpression strain;

[0038] Fig.11 Comparison of tolerance between overexpression strain and original strain. DETAILED DESCRIPTION

[0039] In order to make the purpose, technical solution and advantages of this patent more clear, the following is a further detailed description of this patent in conjunction with specific embodiments. It should be understood that the specific embodiments described here are only used to explain this patent and are not used to limit the present invention.

[0040] The host mycobacterium (Mycobacterium sp.) MNR M3△KsdD used in the present invention is obtained by knocking out the KsdD gene on the basis of Mycobacterium neoaurum (Mycobacterium sp.) MNR M3 (number CICC 21097). The specific strain construction process has been disclosed in Rili Xie, Yanbing Shen, Ning Qin, Yibo Wang, Liqiu Su, Min Wang. Genetic differences in ksdD influence on the ADD / AD ratio of Mycobacterium Neoaurum. Journal of Industrial Microbiology & Biotechnology, 2015, 42: 507-513. Among them, the strain MNR M3 is code-named TCCC 11028M3 in the article, which is the same strain as the (Mycobacterium sp.) MNR M3, number CICC 21097 described in this article.

[0041] The present invention will be further explained below through specific implementation modes.

[0042] Example 1 Taking the AccA1 gene as an example, the construction of the overexpression strain MNR-A is described in detail

[0043] Construct a gene overexpression plasmid of Mycobacterium neogoldensis, electrotransform it into MNR competent cells, and use kanamycin for resistance screening. Pick the positive strains to extract the plasmids, perform single enzyme digestion, double enzyme digestion, and sequencing verification. The bacteria with the correct sequence alignment are MNR-A.

[0044] The specific steps are as follows:

[0045] 1. Overexpression plasmid construction: According to the AccA1 gene sequence information described in SEQ ID No: 1, the (Mycobacterium sp.) MNR M3 (No. CICC 21097) genome was used as a template to design AccA1 gene PCR primers: AccA1-f: GCGGATCCAGCTGCAGAATTCATGGTCAA-CGAACTCTTCCACAC; AccA1-r: TACGTCGACATCGATAAGCTTTCATCGT-TGGGACTCCTTGC.

[0046] The PCR product of the target gene AccA1 was recovered by a purification kit and then seamlessly cloned and connected with the pMV261 linearized vector double-digested with EcoR I and Hind III in vitro to construct the overexpression plasmid pMV261-AccA1.

[0047] 2. Preparation of MNR competent state: Use an inoculation loop to take a loop of MNR glycerol bacteria and streak three zones on an antibiotic-free LB plate, culture at 30℃ for 3 days, pick a single colony into an antibiotic-free LB test tube, culture at 30℃ and 200r / min for 2 days, transfer to a seed culture medium (without calcium carbonate) at a 10% inoculum volume for secondary seed culture; after 36 hours, add 10% glycine (20%) and continue to culture for 24 hours. Pre-cool in an ice bath, collect the bacteria by centrifugation at 4℃, rinse the suspended bacteria with 1 times, 3 / 4 times, 1 / 2 times and 1 / 4 times the volume of the fermentation liquid, respectively, and centrifuge, finally add 1 / 25 times the 10% glycerol to suspend the bacteria, and store in aliquots;

[0048] 3. Electroporation: Take 10 μL of the constructed AccA1 gene overexpression plasmid pMV261-AccA1, add it to 100 μL of competent bacteria, place it for 30 minutes, and then transfer it to an electroporation cup for electroporation. Electroporation conditions are 2 kV / cm, 25 μF, 720Ω, electroporation for 4-6 ms, and then place it on ice for 5 minutes. Add 700 μL of fresh sterilized LB medium to the electroporation cup, mix well, transfer to a 1.5 mL sterilized EP tube, and resuscitate at 30°C and 200 rpm for 4 hours.

[0049] 4. Screening and verification: The revived bacterial liquid was concentrated and spread on LB solid medium containing 20 μg / mL KanR for 5 days. Single colonies were picked and plasmids were extracted. Single and double enzyme digestions and sequencing were performed for verification. The strains with completely consistent sequences or unintentional mutations were obtained as MNR M3△KsdD-AccA1 strains that correctly expressed AccA1, hereinafter referred to as MNR-A strains.

[0050] The construction methods of the other three single gene overexpression strains are the same as that of the AccA1 gene overexpression strain. The schematic diagrams and electrophoresis diagrams of the four single gene overexpression plasmids are shown in Figure 1 , Figure 2 , Figure 3 , Figure 4 As shown, AccA1, AccD1, AraC, and Nat genes were overexpressed in the MNR strain, respectively, to obtain strains MNR M3△KsdD-AccA1 (referred to as MNR-A strain), MNRM3△KsdD-AccD1 (referred to as MNR-D strain), MNR M3△KsdD-AraC (referred to as MNR-C strain), and MNR M3△KsdD-Nat (referred to as MNR-N strain). Using the CICC 21097 genome as a template, after obtaining AccD1, AraC, and Nat genes by PCR, overexpression plasmids were constructed and expressed in MNR. The relevant primers involved in the construction process are as follows:

[0051] According to the AccD1 gene sequence information shown in SEQ ID No: 2, the AccD1 gene PCR primers were designed: AccD1-f: GCGGATCCAGCTGCAGAATTCATGACGCATCGTGAAGCGC;

[0052] ACCD1-R: TACGTCGACATCGATAAGCTTTCA-CATCCTGAAGACGCCGT.

[0053] AraC gene PCR primers were designed according to the AraC gene sequence information shown in SEQ ID No: 3:

[0054] AraC-f: GCGGATCCAGCTGCAGAATTCATGACGCATCGTGAAGCGC;

[0055] AraC-R: TACGTCGACATCGATAAGCTTTCA-CATCCTGAAGACGCCGT.

[0056] Nat gene PCR primers were designed according to the Nat gene sequence information shown in SEQ ID No: 4:

[0057] Nat-f:GCGGATCCAGCTGCAG-AATTCATGACCGTCGATGTGGCCG;

[0058] Nat-R: TACGTCGACATCGATAAG-CTTTCAGTTCCCCAGCACGCG.

[0059] Example 2 Comparison of changes in intracellular propionyl-CoA content between the original strain MNR and the overexpression strains MNR-A / MNR-D / MNR-C / MNR-N at different stages during AD conversion

[0060] The changes in intracellular propionyl-CoA content were detected by high performance liquid chromatography. The original bacteria MNR and four single gene overexpression strains were inoculated in fermentation medium, respectively. When the fermentation medium grew for 168 hours, samples were taken every 24 hours, 1 mL of fermentation broth was taken, and the cells were collected by centrifugation at 4°C. The cells were washed twice with PBS (pH 8.0) buffer, and then resuspended with bacterial lysis buffer (10% trichloroacetic acid 2mM DTT), repeatedly frozen and thawed in liquid nitrogen-ice water for 4 times, and crushed using an ultrasonic cell disruptor (total processing time 5 minutes, working 5 seconds and stopping 5 seconds). The cell mixture after crushing was centrifuged at 4°C, and the supernatant was transferred to a C18 solid phase extraction column. The extraction column was first cleaned with a decontamination solution (1% trifluoroacetic acid), and then the propionyl-CoA in the column was eluted and collected with an eluent (1% trifluoroacetic acid, 40% acetonitrile). The collected liquid was freeze-dried and tested.

[0061] The freeze-dried sample was reconstituted with a mixture of 100 mM ammonium acetate and pure acetonitrile (49:1 V / V), and after dissolution and mixing, the sample was centrifuged and the supernatant was aspirated for testing.

[0062] HPLC conditions: C18 reverse phase column (4.6×250 mm) was used, column temperature was 25° C., and the absorption peak of the sample at 260 nm was detected. Two mobile phases were used for gradient elution, namely 2-12% A (0-5 min), 12-38% A (5-15 min), 38% A (15-17 min), 38-2% A (17-19 min), wherein A was acetonitrile, B was 100 mM ammonium acetate, flow rate was 800 μL / min, and data acquisition was stopped after 30 min.

[0063] The fermentation medium comprises: (NH4)2HPO4 3.5 g / L, K2HPO4 0.5 g / L, MgSO4 0.4 g / L, ammonium ferric citrate 0.05 g / L, citric acid 2 g / L, glucose 10 g / L, phytosterol 5 g / L, and the rest is water, with a pH of 6.8-7.2.

[0064] The results are as follows Figure 5As shown, during the fermentation period, the intracellular propionyl-CoA content of the MNR-C strain was significantly lower than that of MNR, and the difference was most obvious at 96h, which was 38.6% lower than that of MNR. At the same time, the intracellular propionyl-CoA content of the other three single-gene overexpression strains also decreased during sterol metabolism. The AraC gene had the strongest ability to degrade intracellular propionyl-CoA.

[0065] Example 3 Comparison of strain viability and AD transformation ability of single gene overexpression strains

[0066] Strain activation and seed preparation: The original strain MNR and four single gene overexpression strains were transferred to fresh LB medium, cultured at 30°C for 2 days, washed with 20 mL of 0.5% Tween 80 sterile aqueous solution, 1 mL of the eluate was added to 50 mL of seed medium, and cultured in a shaking incubator at 30°C and 200 rpm for 36 hours to obtain seed solution;

[0067] AD production process: The seed solution obtained in step 1 was transferred to the fermentation medium at a 5% inoculation rate and biotransformed at 30°C and 140 rpm for 168 h.

[0068] The seed culture medium consists of: K2HPO4 0.5 g / L, MgSO4 0.5 g / L, ammonium ferric citrate 0.05 g / L, citric acid 2 g / L, ammonium nitrate 2 g / L, glycerol 20 g / L, glucose 5 g / L, CaCO3 1 g / L, and the rest is water, pH 7.2.

[0069] The fermentation medium comprises: (NH4)2HPO4 3.5 g / L, K2HPO4 0.5 g / L, MgSO4 0.4 g / L, ammonium ferric citrate 0.05 g / L, citric acid 2 g / L, glucose 10 g / L, phytosterol 5 g / L, and the rest is water, with a pH of 6.8-7.2.

[0070] Sample detection: Take samples once every 24 hours, take 1 mL of fermentation liquid, add an equal volume of ethyl acetate, and ultrasonicate for 30 minutes. Centrifuge at 14,000 rpm for 10 minutes, aspirate 100 μL of supernatant, dry at room temperature, resuspend the sample with 80% methanol, ultrasonicate for 30 minutes, centrifuge at 14,000 rpm for 10 minutes, aspirate the supernatant, and perform HPLC analysis.

[0071] The parameters of the Agilent l200 chromatograph were set as follows: C18 (4.6×250 mm) column, column temperature 30°C; mobile phase methanol / water (8:2, V / V), flow rate 1 mL / min, detection wavelength 254 nm, injection volume 10 μL, and each sample run for 8 min. AD yield and conversion rate were calculated according to the standard curve.

[0072] Sampling was performed once every 12 h, and 1 mL of the fermentation liquid was taken to detect its absorbance at 600 nM to determine the growth status of each strain.

[0073] Result analysis: According to Figure 6 The results show that the growth state of MNR-C with plasmid load is similar to that of the original strain MNR. This rapid growth ability is very helpful for industrial production. In the early stage of fermentation, the higher the strain biomass, the faster it absorbs substrate sterols in the environment. Compared with other strains, MNR-A grows very slowly and has a small amount of bacteria.

[0074] according to Figure 7 The results showed that the AD molar conversion rate of MNR-A could reach 92.58% at 168h of fermentation, which was 9.62% higher than that of the starting strain MNR at the same time. The overexpression of AccA1 gene promoted the strain's AD conversion. However, in the early stage of fermentation, the MNR-A strain produced almost no AD. The AD molar conversion rate of MNR-C remained at a high level. At 168h, the highest AD molar conversion rate could reach 90.67%, which was 7.73% higher than that of MNR at the same time. Moreover, the AD conversion rate of MNR-C could reach the AD conversion rate of MNR at 168h at 120h of fermentation, which significantly shortened the fermentation cycle.

[0075] Example 4 Construction of AccA1-AraC tandem gene overexpression strain MNR-AC

[0076] AccA1-AraC tandem gene overexpression plasmid was constructed and electroporated into MNR competent cells. Resistance screening was performed using kanamycin. Positive strains were selected to extract plasmids, and single and double enzyme digestion and sequencing were performed for verification. The strain with the correct sequence alignment was MNR-AC.

[0077] The specific steps are as follows: Construction of tandem gene overexpression plasmid: AccA1 gene PCR primers were designed according to the AccA1 gene sequence information described in SEQ ID NO: 1, and AraC gene PCR primers were designed according to the gene sequence information of SEQ ID NO: 3: AccA1-f': GCGGATCCAGCTGCAGAATTCATGGT-CAACGAACTCTTCCACAC;

[0078] AccA1-r':ACCTCTTTTCATCGTTGGGACTCC-TTGC;

[0079] AraC-f': CCCAACGATGAAAAGAGGTGACAGTGAATGCCC;

[0080] AraC-r': TACGTCGACATCGATAAGCTTTTCAGTTACCTCTCATCCATTCCAG.

[0081] The PCR products of AccA1 and AraC were recovered by purification kit and then seamlessly cloned and connected with the pMV261 linearized vector digested with EcoR I and Hind III in vitro to construct the tandem gene overexpression plasmid pMV261-AccA1-AraC.

[0082] The method for constructing the tandem gene overexpression strain is the same as in Example 1. The electrophoresis diagram of the constructed AccA1-AraC tandem gene overexpression plasmid is shown in FIG. Figure 8 The strain obtained after overexpression of AccA1-AraC tandem genes in MNR was named MNR M3

[0083] △KsdD-AccA1-AraC (referred to as MNR-AC strain).

[0084] Example 5 Comparison of the activity and AD transformation ability of the AccA1-AraC tandem gene overexpression strain MNR-AC

[0085] The methods of strain activation, seed preparation, AD transformation process, and sample detection are the same as those in Example 3.

[0086] according to Fig. 9 , Fig.10 The results showed that MNR-AC had a promoting effect on improving the problem of slow growth of strains caused by plasmid load. The growth ability of MNR-AC strain was significantly improved compared with MNR-A. The increase in bacterial mass accelerated the conversion of sterols by the strain. During the entire fermentation process, the sterol conversion ability of MNR-AC was always better than that of MNR-A, and its highest AD conversion rate could reach 94.11%, which was 11.16% higher than that of MNR in the same period. At 144h of fermentation, the AD yield of MNR-AC reached the highest, which was significantly different from the AD yield of MNR, MNR-A and MNR-C in the same period. At the same time, it could reach the yield of MNR-A and MNR-C at 168h, indicating that continuing to tandem the AraC gene in the constructed genetically engineered bacteria can achieve the purpose of improving the growth vitality of the strain, and there is an opportunity to further improve the AD conversion ability of the strain and shorten the conversion cycle.

[0087] Example 6 Product Tolerance Analysis

[0088] The methods of strain activation, seed preparation, and sample testing are the same as those in Example 3.

[0089] The original bacteria and the MNR-AC double gene overexpression strain were transferred to fresh LB medium respectively, cultured at 30°C for 2 days, washed with 20 mL of 0.5% Tween 80 sterile aqueous solution, 1 mL of the eluate was taken and added to 50 mL of seed medium, and cultured in a shaking incubator at 30°C and 200 rpm for 36 hours to obtain seed solution;

[0090] The obtained seed liquid was transferred to a fermentation medium without sterol at an inoculation rate of 5%, and biotransformed at 30° C. and 140 rpm for 48 h.

[0091] Collect the cells and dilute them to OD 600 =1, add AD with final concentrations of 0, 3, and 5 g / L respectively, and observe the changes in bacterial cell mass after 24 hours of growth.

[0092] The seed culture medium consists of: K2HPO4 0.5 g / L, MgSO4 0.5 g / L, ammonium ferric citrate 0.05 g / L, citric acid 2 g / L, ammonium nitrate 2 g / L, glycerol 20 g / L, glucose 5 g / L, CaCO3 1 g / L, and the rest is water, pH 7.2.

[0093] The fermentation medium comprises: (NH4)2HPO4 3.5 g / L, K2HPO4 0.5 g / L, MgSO4 0.4 g / L, ammonium ferric citrate 0.05 g / L, citric acid 2 g / L, glucose 10 g / L, and the rest is water, with a pH of 6.8-7.2.

[0094] according to Fig.11 The results showed that the growth of the strain was measured under different AD concentrations, and it was found that the biomass of MNR-AC increased in high concentrations of sterols, was less affected by AD concentration, and had higher tolerance to AD than the starting strain MNR. The changes in these indicators are one of the reasons for the enhanced biotransformation ability of MNR-AC.

[0095] In summary, the AccA1-AraC tandem gene overexpression strain MNR-AC Mycobacterium genetically engineered bacteria constructed by the present invention can significantly reduce the intracellular propionyl-CoA level of the strain, eliminate the propionyl-CoA toxicity of the strain in the reducing sugar medium, improve cell viability, enhance the strain's tolerance to the product, shorten the conversion cycle of industrial production, and greatly improve the production efficiency of steroid drug precursors.

[0096] The above-mentioned embodiments only express several implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the patent. It should be pointed out that, for ordinary technicians in this field, the above-mentioned implementation methods can also be modified, combined and improved without departing from the concept of this patent, which all belong to the protection scope of this patent. Therefore, the protection scope of this patent shall be based on the attached claims.

Claims

1. A genetically engineered bacterium for producing a steroidal drug precursor, characterized in that: By overexpressing in the host bacteria AraC Genes are used to construct The host bacteria is Mycobacterium ( Mycobacterium sp.)MNR M3△ KDJ ; Said AraC The nucleotide sequence of the gene is shown in SEQ ID NO:

3.

2. The genetically engineered bacterium for producing a steroidal drug precursor according to claim 1, characterized in that In the host mycobacterium MNR M3 △ KDJ Middle Pair AccA1 and AraC The genes are expressed in series to obtain a genetically engineered bacterium that produces a steroid drug precursor; AccA1 The nucleotide sequence of the gene is shown in SEQ ID NO:

1.

3. Use of the genetically engineered bacteria according to claim 1 or 2 in the production of steroid drug precursors.

4. The use according to claim 3, characterized in that The method for producing AD by fermentation using the strain is as follows: The seed liquid of the genetically engineered strain is transferred to the fermentation medium at an inoculation rate of 1%-10%, and cultured at 25-37°C and 100-200rpm for 24-168h.

5. The use according to claim 4, characterized in that The fermentation medium is composed of: (NH4)2HPO4 0.1-4g / L, K2HPO4 0.1-3g / L, MgSO4 0.1-3g / L, ammonium ferric citrate 0.01-0.2g / L, citric acid 1-5g / L, reducing sugar 5-50g / L, sterol 1-50g / L, and the rest is water, pH 6.0-7.5, and is used after high-pressure steam sterilization.